Objectives: Antipsychotics are used to manage the behavioral and psychological symptoms of dementia (BPSD), despite their association with greater risks for mortality and cerebrovascular events. Previous studies in Japan have estimated the prevalence of antipsychotics among older adults who took antidementia drugs. Using long-term care (LTC) data, we aimed to obtain more accurate estimates of the prevalence of antipsychotics and to determine factors related to their use in older adults with dementia.
| INTRODUCTION
Japan has the greatest number of people with dementia among the Organisation for Economic Co-operation and Development countries. 1 This number is projected to increase markedly in the near future, reaching almost one-fifth of the population 2 over 65 years in 2025. This could impose considerable financial and social burdens on both the health care system and society.
One of the major challenges of caring for people with dementia is managing the behavioral and psychological symptoms of dementia (BPSD). 3 Antipsychotics have been used for BPSD management, despite off-label use. 4 Indeed, antipsychotics are associated with greater risks for mortality and cerebrovascular events, which has led regulatory agencies to issue warnings or required pharmaceutical companies to add precautions about the use of antipsychotics for people with dementia. [4] [5] [6] [7] However, antipsychotics have still been commonly prescribed in older adults with dementia in Japan [8] [9] [10] and in overseas countries, 11, 12 even after the issue of such warnings or precautions.
There have been several studies on the use of antipsychotics in older people with dementia in Japan. Based on analyses of large-scale medical claims data, the prevalence of antipsychotic use among people prescribed antidementia drugs [8] [9] [10] ranged from 16.8% to 24.9%. These studies limited their study cohort to those prescribed antidementia drugs partly because a diagnosis of dementia in medical claims is not considered reliable. However, the generalizability of such estimates is limited because people with dementia do not always take antidementia drugs. In fact, the indication for antidementia drugs is generally limited to Alzheimer dementia, with the exception of donepezil, which has been also approved for dementia with Lewy bodies in Japan. Moreover, antidementia drugs are not always prescribed for older adults with dementia for efficacy and safety reasons. 13 Since 2000, Japan has implemented a long-term care (LTC) insurance system that is separate from the medical insurance system. 14 To become beneficiaries of LTC insurance, individuals must have their LTC needs certified through a standardized process involving an assessment of physical and cognitive functions. 15 Lowered cognitive function determined through this process is potentially more clinically relevant than those diagnoses listed in medical claims data 16 ; accordingly, LTC needs certification data might be better able to identify older people with dementia and cognitive decline.
The main objective of this study was to provide a potentially more accurate estimate of the prevalence of antipsychotic use among older adults with dementia, irrespective of whether they have been prescribed antidementia drugs, using medical and LTC data in Japan. As the medical and LTC data can be linked, we are able to identify people with dementia, regardless of whether they are being treated with antidementia drugs. The secondary objective was to determine the factors associated with antipsychotic use in older people with dementia using the LTC certification data.
| MATERIALS AND METHODS

| Data sources
Medical and LTC claims data and LTC certification data over 18 months (April 2012 to September 2013) were obtained from a middle-sized suburban city in the Tokyo metropolitan area of Japan.
Before they were obtained, all data were anonymized; however, unique identification numbers were assigned to each person to enable matching between the medical and LTC data. During the anonymization process, birth year was approximated by converting it to a 5-year range (eg, people born between 1930 and 1934 would be 77-81 years of age as of January 1, 2012). This study was approved by the Ethics Committee of the University of Tsukuba. 
| Study participants
Key points
• Previous studies in Japan determined the prevalence of antipsychotics among individuals prescribed antidementia drugs because of the unavailability of reliable data.
• Use of long-term care data enabled us to obtain more accurate estimates of the prevalence of antipsychotic use in older adults with dementia.
• The new population-based estimate of the prevalence of antipsychotics (10.7%) was lower than that estimated among people prescribed antidementia drugs (16.4%).
• [8] [9] [10] we used the first 12 months of data for our analyses. We also excluded participants who stayed in hospitals or specific types of LTC facilities using bundled payment schemes for more than 6 months in total as their prescription data during their stay there would be unavailable. We could not obtain claims data on medical services for individuals covered by public assistance, so these individuals were not included in the study.
We analyzed the following three cohorts based on our study aims ( Figure 2 ). 2. Antidementia drug users (conventional cohort identification):
These were participants who were prescribed antidementia drugs. We evaluated this cohort to enable a comparison with previous studies. [8] [9] [10] 3. Probable dementia with LTC needs certification data: This group was a subset of the probable dementia cohort defined above for evaluation of associations of factors, including physical and cognitive function, with antipsychotic use. Therefore, in this group, participants that were identified as having probable dementia based on antidementia drug prescription but had not been certified for their LTC needs were excluded.
| Antipsychotic and antidementia drugs
We included both typical and atypical antipsychotic drugs being marketed in Japan during the study period. The typical antipsychotics included bromperidol, carpipramine, chlorpromazine, clocapramine, fluphenazine, haloperidol, levomepromazine, mosapramine, nemonapride, oxypertine, perphenazine, pimozide, pipamperone, prochlorperazine, propericiazine, spiperone, sulpiride, sultopride, timiperone, trifluoperazine, and zotepine. The atypical antipsychotics included aripiprazole, blonanserin, clozapine, olanzapine, paliperidone, perospirone, quetiapine, and risperidone. As a sensitivity analysis, we repeated the analyses while excluding prochlorperazine and sulpiride, as the former is generally used as an antiemetic and the latter for gastric discomfort in Japan.
We included all four antidementia drugs to identify antidementia drug users: donepezil, rivastigmine, galantamine, and memantine. Participants who had at least one outpatient prescription of any of these antidementia drugs during the 12-month study period were defined as antidementia drug users.
| Physical and cognitive function
Activities of daily living associated with dementia and physical disability were only available for participants who had LTC needs certification data. The primary goal of LTC needs certification is to determine both eligibility and individuals' care needs level (which falls into seven grades) based on assessment of physical and cognitive functions; it is usually reassessed once every 12 or 24 months. The assessment procedures are standardized nationwide and involve interviews with the older adult in question and their primary caregiver, as well as a primary care physician's opinion. In this study, the most recent physical and cognitive functions data prior to the study entry were considered.
For cognitive disability, we used the "Independence Degree of Daily Living for the Demented." 17 This measure was validated for identifying people aged greater than or equal to 65 years with dementia in the community with reference to a diagnosis of dementia made by neuropsychiatrists as the gold standard. 16 When people without LTC certification were categorized into those without dementia, the cut-off of rank I on this measure had a 65% sensitivity and a 93% specificity. For people who received LTC services, the validity of this method was improved (83% sensitivity and 92% specificity). 16 It was also reported that most people aged greater than or equal to 65 years with dementia (~80%) had applied for LTC needs certification. 16 We deemed individuals with rank I (almost independent daily living is possible despite having some type of dementia) or greater as having probable dementia. More specifically, individuals were grouped into mild (rank I), moderate (rank II; independent daily life is possible under observation despite daily life-disturbing symptoms, behaviors, and problems with communication), or severe (rank III, requiring assistance; rank IV, requiring assistance frequently; or rank M, marked psychiatric symptoms requiring expert management) cognitive disability.
Physical disability was determined according to the scale of "Independence Degree of Daily Living for the Disabled Elderly"
(Independent, J1/J2, A1/A2, B1/B2, and C1/C2). 17 In this study, these ratings were categorized into "not bedridden" (Independent, J1/J2, and A1/A2) and "bedridden" (B1/B2 and C1/C2). FIGURE 2 Illustration of the study cohorts. LTC, long-term care
| Analysis
The demographics of the study participants were described. The main outcome measure was the prevalence of at least one outpatient prescription of an antipsychotic over the 12-month study period. The prevalence of antipsychotic use was estimated for each study cohort defined above.
We also evaluated the associations of age, gender, antidementia drug use, residential status, hospitalization, and cognitive and physical disability with antipsychotic use among participants with probable dementia whose LTC needs certification data were available. A logistic regression analysis, assessing crude and adjusted odds ratios and 95% confidence intervals, was used for this purpose. Residential status was derived from the LTC claims data. Participants who had at least one claim for institutional LTC services use, including use of one of the three designated types of LTC facilities 18 and other types of facilities or group homes for older people during the 12-month study period, were categorized as LTC facility users. Hospitalization was derived from the medical claims data; participants who had at least one claim for inpatient treatment during the study period were categorized as people who had experienced hospitalization.
As a sensitivity analysis, we repeated the analysis of the 6-month prevalence of antipsychotics in those who had at least 6 months of follow-up. All analyses were performed using Stata version 14 (Stata Corp., College Station, Texas).
| RESULTS
This study included 25 919 participants, among which a quarter were LTC beneficiaries (n = 6106). Participants with probable dementia and antidementia drug users accounted for 18.8% (n = 4865) and 5.8%
(n = 1506), respectively, of the overall sample. When participants with probable dementia were first identified by the use of antidementia drugs (n = 1506; 31.0%), LTC data contributed to identifying an additional 3359 participants (69.0%). Conversely, when LTC data were first used to identify participants with probable dementia (n = 4337; 89.1%), the use of antidementia drugs contributed to identifying an additional 528 participants (10.9%).
The characteristics of people with probable dementia and antidementia drug users, and their proportions of the study population, are shown in Table 1 . The proportion of people with probable dementia increased with age, ranging from 7% to 70%; the proportion of antidementia drug users ranged from 3% to 12% according to age. The difference in proportion between these two cohorts increased with age. Table 2 shows the prevalence of antipsychotic use according to age group, sex, and LTC certification status. The prevalence of antipsychotic use was 10.7% among participants with probable dementia, 16 .4% among antidementia drug users, 2.1% among participants without probable dementia, and 3.8% for the entire study population. In the sensitivity analysis that excluded prochlorperazine and sulpiride, the corresponding prevalence proportions were 9.1%, 14.8%, 0.7%, and 2.3%, respectively (Table S1 ). Among antidementia drug users, atypical antipsychotics were more commonly used, whereas typical antipsychotics were slightly more commonly used among participants with probable dementia (Table 2) . When prochlorperazine and sulpiride were excluded, atypical antipsychotics were more commonly used among all three cohorts (Table S1 ). The 6-month prevalence of antipsychotic use (N = 31 353) was 9.1% among participants with 
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This new prevalence estimate is lower than that derived from antidementia drug users only. A previous study using a nationally representative medical claims database in Japan revealed that the preva- (N = 75 011) and 16.8% (N = 45 437); these latter two estimates were similar to our own among antidementia drug users (16.4%). 9, 10 We also confirm a previously reported shift from typical to atypical antipsychotic use in older people with dementia in Japan. 2011. Although controversy remains about whether memantine has a beneficial effect on BPSD, 22 previous observational studies imply that initiation of memantine reduces the consumption of psychotropics 23 and antipsychotics. 24 More recently, the "Primary Care Physicians' Guideline of Psychotropic Use for BPSD" was published in The strength of this new approach is that it offers greater sensitivity for identifying people with dementia in the population compared with the conventional method using medical claims data only.
Antidementia drug users accounted for only 30% of people with probable dementia, suggesting that the majority of people with dementia could not have been identified in previous studies. [8] [9] [10] The agestratified prevalence of probable dementia in our study was similar to that identified using the Diagnostic and Statistical Manual of Mental Disorders, Third Edition-revised (DSM-III-R) 28 in the latest epidemiological study in Japan. 29 Moreover, the prevalence of antipsychotic use other than prochlorperazine and sulpiride in participants without probable dementia was similar to the prevalence of schizophrenia among individuals aged over 70 years in Japan (male 0.4%, female 0.6%). to receive antipsychotics, our numbers on the prevalence of antipsychotic use might be slightly overestimated. Third, we did not include individuals censored within 12 months after their entry (eg, died) or who had neither medical nor LTC services use during the study period. 
